Treatment with ZBD-2 (1.5 mg/kg) upregulated the levels of TSPO, 5-HT1A and BDNF in PPD models (Fig. 3a, b, c and d). This evidence concerns the gene HTR1A and progressive pseudorheumatoid arthropathy of childhood.